ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

ASCO Annual Meeting Attendance Tops 25,000, Continuing Fast Growth.

May 18, 2001

NIH Drops Objections To Bill For Research On Environmental Causes of Breast Cancer.

May 23, 2008

Smoking Commission Outlines All-Out War On Cigarettes

February 3, 1978

Rapid Non-Invasive Imaging Of Biochemical Composition In Breast Tumor Margins

April 24, 2009

Lame-Duck Session Required To Complete HHS Funding Bill; Nobel Laureates For Gore.

November 10, 2000

Funding opportunities listed.

September 17, 2004